This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
European Medicines Agency. Publication of clinical reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002181.jsp&mid=WC0b01ac058004d5c1 (2 October 2014).
The Council of the European Union. Council adopts new rules on clinical trials. http://www.consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/lsa/142181.pdf (14 April 2014).
US Food and Drug Administration. Fed. Reg. 78, 33421–33423 (2013).
Mello, M.M. et al. N. Engl. J. Med. 369, 1651–1658 (2013).
Roin, B.N. Social Science Research Network http://dx.doi.org/10.2139/ssrn.2337821 (October 10, 2013)
Doshi, P. Br. Med. J. 347, f6754 (2013).
DiMasi, J.A., Reichert, J.M., Feldman, L. & Malins, A. Clin. Pharmacol. Ther. 94, 329–335 (2013).
MEHL/Biophile Int'l Corp. v. Milgraum, 192 F.3d 1362 (1999).
T128/82 (Pyrrolidin-Derivate) Case T 128/82 - Hoffman-La Roche/Pyrrolidine-derivatives O.J. EPO 1984, 164 (Jan. 12, 1984)
G2/08 (Dosage regime/Abbott Respiratory) Case G 2/08 - Dosage regime/Abbott Respiratory 2010 O.J. EPO 456 (Feb. 19, 2010)
Torjesen, I. Br. Med. J. 348, g3432 (2014).
EU Commission, COM/2013/0813 final - 2013/0402 (COD), Proposal for a Directive of the European Parliament and of the Council on the protection of undisclosed know-how and business information (trade secrets) against their unlawful acquisition, use and disclosure. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52013PC0813 (Nov. 28, 2013)
European Federation of Pharmaceutical Industries and Associations. EFPIA welcomes the Commission's Proposal on the protection of undisclosed know-how and business information (“Trade Secrets”). http://www.efpia.eu/mediaroom/129/44/EFPIA-welcomes-the-Commission-39-s-Proposal-on-the-protection-of-undisclosed-know-how-and-business-information-quot-Trade-Secrets-quot (28 November 2013).
Acknowledgements
The authors wish to thank I. Glenn Cohen and the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School for support and advice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Price, W., Minssen, T. Will clinical trial data disclosure reduce incentives to develop new uses of drugs?. Nat Biotechnol 33, 685–686 (2015). https://doi.org/10.1038/nbt.3243
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3243
This article is cited by
-
Are the new clinical trial transparency rules incompatible with the patentability requirements in Europe?
Nature Biotechnology (2018)